Compare Stocks: DSGN, ALMS, GMTX, and CLDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$24.41 -4.5%	$26.06	$3.76 ▼ $31.35	$3.26B	-0.69	924,718 shs	831,497 shs
CLDX Celldex Therapeutics	$42.43 -5.4%	$36.31	$20.37 ▼ $45.14	$3.52B	0.87	1.02 million shs	670,859 shs
DSGN Design Therapeutics	$14.39 -1.8%	$13.04	$4.68 ▼ $17.25	$917.45M	1.63	465,604 shs	406,836 shs
GMTX Gemini Therapeutics	$80.59 -0.8%	$74.16	$1.16 ▼ $14.10	$3.49B	-0.12	189,291 shs	263,481 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	-4.46%	-12.19%	-10.52%	+6.73%	+452.26%
CLDX Celldex Therapeutics	-5.04%	+2.53%	+11.63%	+35.96%	+70.51%
DSGN Design Therapeutics	-1.84%	+4.50%	+5.27%	+0.14%	+165.50%
GMTX Gemini Therapeutics	-0.76%	+2.13%	+6.07%	+15.62%	+36.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$24.41 -4.5%	$26.06	$3.76 ▼ $31.35	$3.26B	-0.69	924,718 shs	831,497 shs
CLDX Celldex Therapeutics	$42.43 -5.4%	$36.31	$20.37 ▼ $45.14	$3.52B	0.87	1.02 million shs	670,859 shs
DSGN Design Therapeutics	$14.39 -1.8%	$13.04	$4.68 ▼ $17.25	$917.45M	1.63	465,604 shs	406,836 shs
GMTX Gemini Therapeutics	$80.59 -0.8%	$74.16	$1.16 ▼ $14.10	$3.49B	-0.12	189,291 shs	263,481 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	-4.46%	-12.19%	-10.52%	+6.73%	+452.26%
CLDX Celldex Therapeutics	-5.04%	+2.53%	+11.63%	+35.96%	+70.51%
DSGN Design Therapeutics	-1.84%	+4.50%	+5.27%	+0.14%	+165.50%
GMTX Gemini Therapeutics	-0.76%	+2.13%	+6.07%	+15.62%	+36.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALMS Alumis	2.83	Moderate Buy	$40.30	65.10% Upside
CLDX Celldex Therapeutics	2.86	Moderate Buy	$55.46	30.16% Upside
DSGN Design Therapeutics	2.88	Moderate Buy	$16.50	14.66% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest DSGN, ALMS, GMTX, and CLDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$40.00 ➝ $46.00
8/7/2026	CLDX Celldex Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $53.00
8/3/2026	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$25.00
7/29/2026	CLDX Celldex Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $72.00
7/22/2026	CLDX Celldex Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$54.00 ➝ $48.00
7/22/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$44.00 ➝ $40.00
7/22/2026	CLDX Celldex Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$67.00 ➝ $61.00
7/22/2026	CLDX Celldex Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$62.00 ➝ $60.00
7/20/2026	CLDX Celldex Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$90.00 ➝ $100.00
7/17/2026	CLDX Celldex Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	DSGN Design Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALMS Alumis	$24.05M	129.40	N/A	N/A	$2.88 per share	8.48
CLDX Celldex Therapeutics	$1.54M	2,172.83	N/A	N/A	$9.10 per share	4.68
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.23 per share	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALMS Alumis	-$243.32M	-$1.98	N/A	N/A	N/A	-2,825.70%	-88.79%	-70.72%	N/A
CLDX Celldex Therapeutics	-$258.76M	-$4.35	N/A	N/A	N/A	N/A	-52.35%	-47.61%	N/A
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	N/A
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A

Latest DSGN, ALMS, GMTX, and CLDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ALMS Alumis	-$0.7290	-$0.78	-$0.0510	-$1.11	$3.47 million	$1.66 million
8/6/2026	Q2 2026	CLDX Celldex Therapeutics	-$1.06	-$0.94	+$0.12	-$0.94	$0.74 million	$0.02 million
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A
5/14/2026	Q1 2026	ALMS Alumis	-$0.7318	-$0.74	-$0.0082	-$0.74	$2.10 million	$1.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALMS Alumis	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALMS Alumis	N/A	7.51	7.51
CLDX Celldex Therapeutics	N/A	11.82	11.82
DSGN Design Therapeutics	N/A	18.86	18.86
GMTX Gemini Therapeutics	N/A	71.49	71.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALMS Alumis	N/A
CLDX Celldex Therapeutics	N/A
DSGN Design Therapeutics	56.64%
GMTX Gemini Therapeutics	75.42%

Insider Ownership

Company	Insider Ownership
ALMS Alumis	33.70%
CLDX Celldex Therapeutics	5.20%
DSGN Design Therapeutics	17.10%
GMTX Gemini Therapeutics	12.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALMS Alumis	N/A	127.49 million	84.53 million	N/A
CLDX Celldex Therapeutics	150	78.53 million	74.45 million	Optionable
DSGN Design Therapeutics	40	62.58 million	51.88 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable

DSGN, ALMS, GMTX, and CLDX Headlines

Recent News About These Companies

FDA reversals leave investors worrying about the fates of other experimental drugs

March 6, 2026 | cnbc.com

What Is Gemini? Everything You Should Know About Google's AI Tool

October 17, 2024 | cnet.com

Google Gemini could soon get a lot more useful on your phone

July 31, 2024 | androidpolice.comA

Gemini Review 2024: Is This Crypto Exchange a Gem for Your Investments?

July 22, 2024 | businessinsider.com

ChatGPT vs. Microsoft Copilot vs. Gemini: Which is the best AI chatbot?

May 23, 2024 | zdnet.comZ

Gemini Monthly Horoscope: May 2024

May 2, 2024 | pedestrian.tvP

Google's Gemini AI Will Work On Your Pixel 2 XL—Android 10, 11 Devices Now Supported

April 28, 2024 | techtimes.comT

Comparing ChatGPT 3.5, Microsoft Bing, and Google Gemini in diagnosing cases of neuro-ophthalmology

April 17, 2024 | ophthalmologytimes.comO

Google's public release of Gemini 1.5 should build trust, Deutsche Bank says

April 17, 2024 | seekingalpha.com

Google takes down Gemini AI image generator. Here’s what you need to know.

February 26, 2024 | washingtonpost.com

‘White privilege is f–king real’: Google Gemini product lead’s old tweets allegedly resurface amid ‘woke’ AI image fiasco

February 26, 2024 | nypost.comN

Google Gemini: Everything you need to know about Google's Answer to ChatGPT – Updated December 2023

December 9, 2023 | androidheadlines.comA

Gemini Review 2023: Pros, Cons and How It Compares

November 16, 2023 | nerdwallet.comN

Yesterday's Gemini Horoscope

October 5, 2023 | yourtango.comY

Gemini Tarot Horoscopes: October 2023

October 3, 2023 | glamour.comG

Yearly Gemini Tarot Card Reading

August 28, 2023 | yourtango.comY

Move over Bard, Google's next big AI product is coming this fall

August 19, 2023 | androidauthority.comA

Radar In Space: The Gemini Rendezvous Radar

July 27, 2023 | hackaday.comH

Sun Transit in Gemini- The twins love the Sun’s visit

July 13, 2023 | prokerala.comP

Sun Transit in Gemini: Sun with Dual energies?

July 5, 2023 | prokerala.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN, ALMS, GMTX, and CLDX Company Descriptions

Alumis NASDAQ:ALMS

$23.94 -1.61 (-6.32%)

As of 09:30 AM Eastern

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Celldex Therapeutics NASDAQ:CLDX

$42.42 -2.45 (-5.45%)

As of 09:30 AM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Design Therapeutics NASDAQ:DSGN

$14.53 -0.13 (-0.90%)

As of 09:30 AM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Gemini Therapeutics NASDAQ:GMTX

$80.59 -0.62 (-0.76%)

As of 08/12/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DSGN, ALMS, GMTX, and CLDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DSGN, ALMS, GMTX, and CLDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DSGN, ALMS, GMTX, and CLDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN, ALMS, GMTX, and CLDX Company Descriptions

Alumis NASDAQ:ALMS

Celldex Therapeutics NASDAQ:CLDX

Design Therapeutics NASDAQ:DSGN

Gemini Therapeutics NASDAQ:GMTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DSGN, ALMS, GMTX, and CLDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DSGN, ALMS, GMTX, and CLDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DSGN, ALMS, GMTX, and CLDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN, ALMS, GMTX, and CLDX Company Descriptions

Alumis NASDAQ:ALMS

Celldex Therapeutics NASDAQ:CLDX

Design Therapeutics NASDAQ:DSGN

Gemini Therapeutics NASDAQ:GMTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools